New York, USA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight The BRAF Inhibitors market is expected ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

(MENAFN- GlobeNewsWire - Nasdaq) The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

“Accordingly, we plan to add three new phase 2a combination arms: IMM-1-104 with a BRAF inhibitor in BRAF-mutant melanoma, and IMM-1-104 with an immune checkpoint inhibitor in both melanoma and ...